Keyphrases
Body Mass Index
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Improved Survival
100%
Increased Body Mass Index
100%
United States Veterans
100%
Obese Patients
37%
Risk of Death
37%
Hazard Ratio
25%
Working Diagnosis
25%
Overall Survival
25%
Disease-related
25%
Non-Hodgkin Lymphoma
25%
Overweight Patient
25%
Cox Analysis
25%
Malignancy
12%
Risk Reduction
12%
Age at Diagnosis
12%
Obesity
12%
Prognostic Factors
12%
Patient-specific
12%
Weight Loss
12%
Overweight or Obesity
12%
B Symptoms
12%
Normal Weight
12%
Retrospective Cohort
12%
Most Common Form
12%
Reduced Mortality
12%
Lymphoma Diagnosis
12%
Weighted Data
12%
Low Stage
12%
Rituximab Era
12%
Nursing and Health Professions
Body Mass
100%
Diffuse Large B Cell Lymphoma
100%
Obesity
55%
Diseases
33%
Overall Survival
22%
Hazard Ratio
22%
Nonhodgkin Lymphoma
22%
Rituximab
11%
Pharmacology, Toxicology and Pharmaceutical Science
Obesity
100%
Diffuse Large B Cell Lymphoma
100%
Diseases
60%
Overall Survival
40%
Nonhodgkin Lymphoma
40%
Rituximab
20%
Biochemistry, Genetics and Molecular Biology
Body Mass
100%
B Cell
100%
Overall Survival
22%
Rituximab
11%